0000000000346923

AUTHOR

Giovanni Brandi

showing 4 related works from this author

Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line soraf…

2019

Abstract Background REACH (NCT01140347) and REACH-2 (NCT02435433) were two global, randomized, double-blind, placebo (PL)-controlled multicenter, phase 3 studies of RAM vs PL in patients with HCC after prior sorafenib. REACH-2 confirmed overall survival (OS) benefit of RAM for patients with baseline AFP ≥400ng/mL, consistent with results in a prespecified subgroup of patients in REACH with AFP ≥400ng/mL. Methods Post-hoc pooled analyses were performed to examine efficacy and safety in three age subgroups ( Results Both intention-to-treat populations were pooled (542 patients in total). Within each age subgroup, baseline characteristics between treatment arms were similar. Patients of Conclu…

Entire populationeducation.field_of_studyPhase iii trialsbusiness.industryFirst linePopulationHematologyDose intensityManagementOncologyBaseline characteristicsOverall survivalMedicineIn patienteducationbusinessAnnals of Oncology
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

2020

Background & Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years). Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods …

Sorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinoma[SDV.CAN]Life Sciences [q-bio]/CancerSorafenib intolerancePlaceboAntibodies Monoclonal HumanizedGastroenterologyRamucirumabRamucirumabCàncer de fetge03 medical and health sciences0302 clinical medicineElderlyInternal medicineCox proportional hazards regressionMedicineHumansAgedHepatologyElevated alpha-fetoproteinbusiness.industryPersones grans dependentsHazard ratioLiver Neoplasms[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyHepatitis CSorafenibmedicine.diseaseFrail elderly3. Good healthVEGFR2Treatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030211 gastroenterology & hepatologyMonoclonal antibodiesAlpha-fetoprotein (AFP)alpha-FetoproteinsbusinessAnticossos monoclonalsLiver cancermedicine.drugLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

2021

<b><i>Introduction:</i></b> Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated. <b><i>Methods:</i></b> We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy. <b><i>Results:</i></b> Ninety-six…

OncologySorafenibmedicine.medical_specialtyCabozantinibHepatocellular carcinomaContext (language use)chemistry.chemical_compoundInternal medicineCabozantinib; Hepatocellular carcinoma; Outcome; Sorafenib; Tyrosine kinase inhibitorsmedicineAdverse effectRC254-282OutcomeTyrosine kinase inhibitorsSettore MED/12 - GastroenterologiaOriginal PaperHepatologyPerformance statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCabozantinibSorafenibmedicine.diseaseClinical trialOncologychemistryHepatocellular carcinomaLiver functionbusinessmedicine.drug
researchProduct